Open-Label, Randomized, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension

Trial Profile

Open-Label, Randomized, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Dimethyl fumarate (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CONNECT
  • Sponsors Biogen
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 07 Jul 2016 Planned End Date changed from 1 Sep 2020 to 1 Jan 2025.
    • 07 Jul 2016 Planned primary completion date changed from 1 Sep 2020 to 1 May 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top